RSS Feed Print
Nerve Growth Factor Study
Myriam
Posted: Friday, March 30, 2012 1:23 PM
Joined: 12/6/2011
Posts: 3326


From Alzheimer's Daily News:


(Source: ADCS) - A Phase II clinical study of Ceregene's CERE-110, a gene therapy product designed to deliver nerve growth factor (NGF) to the brain for the treatment of Alzheimer's disease is currently underway. This study is currently enrolling participants.

This Phase II study is a randomized, double blind, placebo-controlled trial and employs gene therapy to deliver nerve growth factor (NGF) directly into the brain. The rationale behind this study is that NGF is known to promote survival of certain neurons, called cholinergic neurons, that degenerate in AD, and therefore may provide sustained functioning of these neurons. Direct delivery of CERE-110 into the brain aims to selectively target the Nucleus Basalis of Meynert (NBM), where cholinergic neuronal degeneration occurs in AD.

A Phase I study at Rush University and the University of California (SD) indicated that a single administration of the therapy was generally safe and well tolerated. This Phase II study will examine the safety and effectiveness of NGF on Alzheimer's disease in 50 patients at 11 research sites throughout the United States.

To learn how to participate contact one of the centers or contact the NIA's Alzheimer's Disease Education and Referral (ADEAR) Center at (800) 438-4380 or by email to adear@nia.nih.gov. To view a list of the research sites or for information on dementia and aging, go to ADEAR.

Go to full story: http://adcs.org